SCHEMBL2411477

SCHEMBL2411477

COc1ccc(-c2cccc(N3CCC(CN(Cc4cscn4)C(=O)O)CC3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
RAB9A P51151 3/20 0.39
NEK2 P51955 1/20 0.38
MAPT P10636 5/20 0.37
ALDH1A1 P00352 5/20 0.36
NPC1 O15118 2/20 0.36
LMNA P02545 4/20 0.36
MAPK1 P28482 2/20 0.36
TP53 P04637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
ACP1 P24666 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
GLA P06280 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406949 0.92 CNR1 (0.39) CNR1SMN1; SMN2RAB9ANEK2MAPT
SCHEMBL2405627 0.89 CNR1 (0.38) CNR1RAB9AMAPTNPC1
SCHEMBL2406148 0.88 HSD11B1 (0.38)
SCHEMBL2406555 0.88 KDM4E (0.39) NEK2LMNAHSD17B10MEN1KMT2A
SCHEMBL2406060 0.87 DKK1 (0.42) CNR1SMN1; SMN2RAB9ANPC1
SCHEMBL2404007 0.87 CPT2 (0.35) PKMGAA
SCHEMBL2408758 0.86 FFAR4 (0.36) CNR1SMN1; SMN2HSD17B10
SCHEMBL2411198 0.85 PIM1 (0.36)
SCHEMBL2405641 0.85 FFAR4 (0.32) CNR1
SCHEMBL2405902 0.85 FFAR4 (0.41) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912218-B2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-12-16 US disclosed
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MET, ALK, REL CNR1 39/4885SMN1; SMN2 4624/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.